JPRN-UMIN000044470已完成未知
A phase Ib study of Durvalumab in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer. An additional study for immunological prognostic factors - A phase Ib study of Durvalumab in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer. An additional study for immunological prognostic factors
ational Institutes for Quantum and Radiological Science and Technology0 个研究点目标入组 10 人开始时间: 2021年6月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Patients who are judged by the investigator or other physician to be unsuitable for participation in this study, such as those who are unlikely to comply with study procedures, restrictions, or requirements.
研究者
相似试验
已完成
1 期
A phase Ib study of Durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancerD002583cervical cancerJPRN-jRCT2031210083Murata Kazutoshi10
进行中（未招募）
1 期
A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)EUCTR2016-003998-17-BEGrand Hôpital de Charleroi57
尚未招募
不适用
A phase II study of daratumumab in combination with bortezomib and dexamethasone in patients with multiple myeloma who received 1 prior line of therapyKCT0004352Samsung Medical Center26
已完成
2 期
ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer2024-511847-24-00Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH40
招募中
2 期
IMMUWIN - A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT
for intermediate stage HCC2024-513950-32-00Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH55